

Alessio Aghemo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7632009/alessio-aghemo-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

281
papers

9,381
citations

43
h-index

91
g-index

400
ext. papers

11,904
ext. citations

4.9
avg, IF

6.74
L-index

#	Paper	IF	Citations
281	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018 , 69, 461-511	13.4	1079
280	EASL Clinical Practice Guidelines: management of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2011 , 55, 245-64	13.4	983
279	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020 , 383, 1522-1534	59.2	913
278	A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. <i>Hepatology</i> , 2012 , 56, 532-43	11.2	279
277	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , 2020 , 73, 1170-1218	13.4	237
276	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 135-184	18.8	216
275	Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. <i>Hepatology</i> , 2011 , 53, 791-9	11.2	199
274	Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. <i>Gastroenterology</i> , 2010 , 138, 108-15	13.3	173
273	EASL recommendations on treatment of hepatitis C 2014. <i>Journal of Hepatology</i> , 2014 , 61, 373-95	13.4	161
272	High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , 2020 , 73, 1063-1071	13.4	158
271	Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2017 , 166, 109-117	8	138
270	Recommendations for the management of hepatitis C virus infection among people who inject drugs. <i>International Journal of Drug Policy</i> , 2015 , 26, 1028-38	5.5	132
269	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017 , 7, 4492	4.9	131
268	New horizons in hepatitis C antiviral therapy with direct-acting antivirals. <i>Hepatology</i> , 2013 , 58, 428-38	11.2	118
267	The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. <i>Journal of Hepatology</i> , 2013 , 59, 251-6	13.4	106
266	Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. <i>Hepatology</i> , 2011 , 54, 1127-34	11.2	105
265	Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. <i>Hepatology</i> , 2010 , 52, 249-55	11.2	103

264	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. <i>Gut</i> , 2015 , 64, 1824-33	19.2	99
263	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 125-133	18.8	98
262	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2019 , 70, 379-387	13.4	87
261	Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	86
260	Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. <i>Journal of Hepatology</i> , 2016 , 64, 1217-23	13.4	84
259	A review of the treatment of chronic hepatitis C virus infection in cirrhosis. <i>Clinical Therapeutics</i> , 2010 , 32, 2117-38	3.5	80
258	Impact of COVID-19 on global HCV elimination efforts. <i>Journal of Hepatology</i> , 2021 , 74, 31-36	13.4	80
257	Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. <i>Hepatology</i> , 2012 , 56, 1681-7	11.2	75
256	Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 193-207	5.4	73
255	Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. <i>Internal and Emergency Medicine</i> , 2012 , 7, 139-44	3.7	73
254	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. <i>Hepatology</i> , 2012 , 55, 336-42	11.2	67
253	Direct-acting antivirals: the endgame for hepatitis C?. <i>Current Opinion in Virology</i> , 2017 , 24, 31-37	7.5	62
252	High levels of factor VIII and risk of extra-hepatic portal vein obstruction. <i>Journal of Hepatology</i> , 2009 , 50, 916-22	13.4	62
251	The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat. <i>Journal of Hepatology</i> , 2018 , 69, 1188-1196	13.4	62
250	Vasculitis changes in COVID-19 survivors with persistent symptoms: an [F]FDG-PET/CT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1460-1466	8.8	56
249	Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010 , 7, 485-94	24.2	54
248	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. <i>Journal of Autoimmunity</i> , 2020 , 114, 102511	15.5	53
247	Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1183-1191.e7	6.9	53

246	Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. <i>Hepatology</i> , 2010 , 52, 1723-30	11.2	51
245	Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. <i>Heart</i> , 2020 , 106, 1512-1518	5.1	51
244	Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. <i>Journal of Hepatology</i> , 2013 , 59, 38-44	13.4	47
243	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. <i>Hepatology</i> , 2015 , 62, 111-7	11.2	46
242	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. <i>Gastroenterology</i> , 2021 , 160, 2435-2450.e34	13.3	45
241	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 52-62	18.8	43
240	Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 90-8	3.4	43
239	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019 , 9, 3682	4.9	42
238	Management of patients with autoimmune liver disease during COVID-19 pandemic. <i>Journal of Hepatology</i> , 2020 , 73, 453-455	13.4	40
237	Contribution of β cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. <i>Journal of Hepatology</i> , 2015 , 63, 1484-90	13.4	38
236	Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?. <i>Liver International</i> , 2017 , 37, 950-962	9.2	36
235	Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 412-414	6.4	36
234	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. <i>Journal of Hepatology</i> , 2019 , 71, 1106-1115	13.4	36
233	Hepatitis C treatment in patients with kidney disease. <i>Kidney International</i> , 2013 , 84, 874-9	9.9	36
232	Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. <i>Gut</i> , 2016 , 65, 1998-2006	19.2	35
231	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2366-2368.e3	6.9	35
230	The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. <i>Antiviral Therapy</i> , 2011 , 16, 677-84	1.6	34
229	Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. <i>Journal of Hepatology</i> , 2014 , 60, 913-9	13.4	33

228	Role of liver biopsy in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019 , 25, 6041-6052	5.6	33
227	Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review. <i>Liver Cancer</i> , 2020 , 9, 15-27	9.1	33
226	Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1434-42	6.1	32
225	Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. <i>Liver Transplantation</i> , 2015 , 21, 1259-65	4.5	31
224	Liver tests abnormalities in COVID-19: trick or treat?. <i>Journal of Hepatology</i> , 2020 , 73, 1275-1276	13.4	30
223	Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 3187-3197	8.8	30
222	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. <i>Liver International</i> , 2017 , 37, 1526-1534	7.9	29
221	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. <i>Hepatology</i> , 2016 , 63, 418-27	11.2	29
220	Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1331-6	6.9	29
219	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019 , 51, 310-317	3.3	29
218	The pattern of pegylated interferon- α 2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , 2009 , 14, 577-584	1.6	28
217	Liver stiffness measurement reliability and main determinants of point shear-wave elastography in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 356-65	6.1	27
216	Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 858-66	3.4	27
215	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. <i>Nutrients</i> , 2019 , 11,	6.7	27
214	Gastroenterology department operational reorganisation at the time of covid-19 outbreak: an Italian and Chinese experience. <i>Gut</i> , 2020 , 69, 981-983	19.2	26
213	Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. <i>Digestive and Liver Disease</i> , 2014 , 46, 152-6	3.3	26
212	Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. <i>Seminars in Immunopathology</i> , 2013 , 35, 111-20	12	25
211	Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. <i>Journal of Hepatology</i> , 2009 , 51, 288-95	13.4	25

210	Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. <i>Digestive and Liver Disease</i> , 2013 , 45, 1-7	3.3	23
209	Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. <i>European Journal of Internal Medicine</i> , 2008 , 19, 370-1	3.9	23
208	Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 944-9	3.4	22
207	Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. <i>Journal of Hepatology</i> , 2012 , 57, 1326-35	13.4	22
206	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020 , 52, 937-941	3.3	22
205	Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?. <i>Liver International</i> , 2015 , 35, 1-4	7.9	21
204	High mortality in COVID-19 patients with mild respiratory disease. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13314	4.6	21
203	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. <i>Liver International</i> , 2018 , 38, 1459-1467	7.9	21
202	High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1705-1712	6.1	21
201	Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature. <i>Liver International</i> , 2016 , 36, 1585-1589	7.9	21
200	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021 , 41, 1227-1242	7.9	20
199	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. <i>British Journal of Haematology</i> , 2021 , 193, 43-51	4.5	20
198	Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. <i>Digestive and Liver Disease</i> , 2013 , 45, 43-9	3.3	19
197	Gastrointestinal involvement attenuates COVID-19 severity and mortality 2020 ,		19
196	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. <i>PLoS ONE</i> , 2016 , 11, e0155967	3.7	19
195	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. <i>Journal of Autoimmunity</i> , 2019 , 100, 17-26	15.5	18
194	Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. <i>Hepatic Medicine: Evidence and Research</i> , 2014 , 6, 25-33	3.4	18
193	Hyporesponsiveness to PegIFN α B plus ribavirin in patients with hepatitis C-related advanced fibrosis. <i>Journal of Hepatology</i> , 2012 , 56, 341-7	13.4	18

192	Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2009 , 7, 925-35	5.5	18
191	The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 7213-24	6.3	17
190	Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. <i>Journal of Hepatology</i> , 2012 , 56, 1209-1210	13.4	17
189	Hepatorenal syndrome and novel advances in its management. <i>Kidney and Blood Pressure Research</i> , 2013 , 37, 588-601	3.1	17
188	Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. <i>Antiviral Therapy</i> , 2014 , 19, 527-31	1.6	17
187	HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. <i>Journal of Hepatology</i> , 2009 , 51, 964-6	13.4	17
186	Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies. <i>World Journal of Gastroenterology</i> , 2013 , 19, 1359-71	5.6	17
185	The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy. <i>International Journal of Cardiology</i> , 2021 , 324, 249-254	3.2	17
184	Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2019 , 51, 1135-1140	3.3	16
183	Treatment of Extrahepatic Manifestations of Hepatitis C Virus. <i>Clinics in Liver Disease</i> , 2017 , 21, 631-643	4.6	16
182	US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C. <i>Radiology</i> , 2005 , 234, 641; author reply 641	20.5	16
181	The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , 2009 , 14, 577-84	1.6	16
180	Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1966-72	0.7	15
179	Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. <i>Liver International</i> , 2017 , 37, 1295-1303	7.9	14
178	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017 , 49, 731-741	3.3	14
177	Short-term health-related quality of life, physical function and psychological consequences of severe COVID-19. <i>Annals of Intensive Care</i> , 2021 , 11, 91	8.9	14
176	Impaired Response to Interferon- α 2b plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection. <i>Antiviral Therapy</i> , 2006 , 11, 797-802	1.6	14
175	Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2019 , 23, 2216-2224	3.3	13

174	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
173	Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir. <i>PLoS ONE</i> , 2014 , 9, e95881	3.7	13
172	PegIFN- α for the treatment of chronic hepatitis B and C: a 10-year history. <i>Expert Review of Anti-Infective Therapy</i> , 2013 , 11, 459-74	5.5	13
171	Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 301-13	5.4	13
170	The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. <i>Antiviral Therapy</i> , 2009 , 14, 789-96	1.6	13
169	Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. <i>Liver International</i> , 2020 , 40, 778-786	7.9	13
168	Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe. <i>Journal of Hepatology</i> , 2017 , 66, S95-S96	13.4	12
167	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016 , 48, 995-1005	3.3	12
166	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 739-50	5.1	12
165	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 12-19	3.4	12
164	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021 , 74, 801-810	13.4	12
163	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma. <i>PLoS ONE</i> , 2020 , 15, e0232371	3.7	11
162	Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. <i>Liver International</i> , 2020 , 40, 769-777	7.9	11
161	Ledipasvir/Sofosbuvir for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 Hcv Infection. <i>Journal of Hepatology</i> , 2016 , 64, S183	13.4	11
160	How to optimize HCV therapy in genotype 2 patients. <i>Liver International</i> , 2013 , 33 Suppl 1, 35-40	7.9	11
159	Estimating HCV disease burden - volume 3 (editorial). <i>Journal of Viral Hepatitis</i> , 2015 , 22 Suppl 4, 1-3	3.4	11
158	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 , 7, 396-415	18.8	11
157	Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 416-23	3.4	10

156	Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 G allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. <i>Journal of Clinical Virology</i> , 2014 , 59, 274-5	14.5	10
155	Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. <i>Hepatitis Monthly</i> , 2011 , 11, 918-24	1.8	10
154	Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. <i>Hepatitis Monthly</i> , 2012 , 12, 411-4	1.8	10
153	Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 1373-1383	4.2	10
152	Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). <i>Digestive and Liver Disease</i> , 2014 , 46, 18-24	3.3	9
151	Treatment of patients with dual hepatitis B and C: a step in the right direction. <i>Gut</i> , 2014 , 63, 380-1	19.2	9
150	Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 875-82	3.4	9
149	Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C. <i>PLoS ONE</i> , 2014 , 9, e106022	3.7	9
148	Stay (GI) Healthy: COVID-19 and Gastrointestinal Manifestations. <i>Techniques and Innovations in Gastrointestinal Endoscopy</i> , 2021 , 23, 179-189	1.3	9
147	Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study. <i>Journal of Hepatology</i> , 2018 , 68, S65	13.4	8
146	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014 , 46, 818-25	3.3	8
145	Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 473-84	4.1	8
144	COVID-19 and the liver: A 2021 update. <i>Liver International</i> , 2021 , 41, 1988-1998	7.9	8
143	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. <i>Liver International</i> , 2021 , 41, 1802-1814	7.9	8
142	Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report. <i>Hepatology Communications</i> , 2018 , 2, 1179-1183	6	8
141	What do clinicians need to watch for with direct-acting antiviral therapy?. <i>Journal of the International AIDS Society</i> , 2018 , 21 Suppl 2, e25076	5.4	7
140	Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012 , 19 Suppl 1, 3-6	3.4	7
139	Comparative trials of peginterferon αa and peginterferon αb for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012 , 19 Suppl 1, 37-41	3.4	7

138	Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review. <i>Kidney and Blood Pressure Research</i> , 2013 , 38, 52-60	3.1	7
137	Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 1997-2005	15.4	7
136	Treatment of patients with HCV related cirrhosis: many rewards with very few risks. <i>Hepatitis Monthly</i> , 2012 , 12, 361-8	1.8	7
135	Cirrhosis regression in chronic hepatitis C: an old tale with a new ending. <i>Gastroenterology</i> , 2009 , 136, 1447-9	13.3	7
134	Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity. <i>PLoS ONE</i> , 2015 , 10, e0138546	3.7	7
133	Clinical Management of Nonrespiratory Diseases in the COVID-19 Pandemic: What Have We Done and What Needs to Be Done?. <i>Telemedicine Journal and E-Health</i> , 2020 , 26, 1206-1208	5.9	7
132	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021 , 53, 677-681	3.3	7
131	Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements. <i>Liver International</i> , 2021 , 41, 649-655	7.9	7
130	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615	5.8	7
129	Lack of Rapid Virological Response Predicts Interferon- α 2b/Ribavirin Therapy failure in HCV Genotype 2 Patients: A Single-Centre Study. <i>Antiviral Therapy</i> , 2007 , 12, 1033-1040	1.6	7
128	Daclatasvir for the treatment of chronic hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2679-88	4	6
127	Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients. <i>Antiviral Therapy</i> , 2014 , 19, 747-53	1.6	6
126	Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 1067-76	7	6
125	Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin?. <i>Medical Hypotheses</i> , 2012 , 79, 471-3	3.8	6
124	Peginterferon Alfa-2B versus peginterferon Alfa-2A with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal. <i>Gastroenterology</i> , 2010 , 138, 386-9; discussion 389-90	13.3	6
123	HBV and HCV therapy. <i>Viruses</i> , 2009 , 1, 484-509	6.2	6
122	Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy. <i>Hepatology</i> , 2010 , 52, 1170-1	11.2	6
121	Deciding on Interferon-Free Treatment for Chronic Hepatitis C: Updating Liver Stiffness Cut-Off Values to Maximize Benefit. <i>PLoS ONE</i> , 2016 , 11, e0164452	3.7	6

120	Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure. <i>Clinical and Molecular Hepatology</i> , 2019 , 25, 360-365	6.9	6
119	Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. <i>Hepatitis Monthly</i> , 2011 , 11, 918-924	1.8	6
118	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. <i>Digestive and Liver Disease</i> , 2020 , 52, 190-198	3.3	6
117	Reply to: Correspondence on "High rates of 30-day mortality in patients with cirrhosis and COVID-19". <i>Journal of Hepatology</i> , 2020 , 73, 1570-1571	13.4	6
116	Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients. <i>Med</i> , 2021 , 2, 435-447.e4	31.7	6
115	Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. <i>Antiviral Therapy</i> , 2006 , 11, 797-802	1.6	6
114	Screening of oesophagogastric varices in virus-related compensated advanced chronic liver disease: Beyond the Baveno VI criteria. <i>Digestive and Liver Disease</i> , 2017 , 49, e38	3.3	5
113	JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. <i>Hepatology</i> , 2019 , 69, 2349-2363	11.2	5
112	Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. <i>Gut</i> , 2015 , 64, 860-219.2	19.2	5
111	Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up. <i>International Journal of Artificial Organs</i> , 2018 , 41, 306-318	1.9	5
110	De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review). <i>Digestive Diseases and Sciences</i> , 2014 , 59, 691-5	4	5
109	P1032 LOW ACCURACY OF NON-INVASIVE TESTS FOR ASSESSING RESIDUAL CIRRHOSIS IN HEPATITIS C PATIENTS WITH A SUSTAINED VIROLOGICAL RESPONSE. <i>Journal of Hepatology</i> , 2014 , 60, S418-S419	13.4	5
108	Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus. <i>Gastroenterology</i> , 2013 , 145, 247-249	13.3	5
107	High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study. <i>Liver International</i> , 2020 , 40, 1062-1068	7.9	5
106	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 117-138	13.8	5
105	The Prevalence, Clinical Features and Response to Antiviral Therapy of Patients with Chronic Hepatitis C who are Seropositive for LiverKidney Microsome Type 1 Antibodies. <i>Antiviral Therapy</i> , 2005 , 10, 715-720	1.6	5
104	Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals?. <i>Journal of Hepatology</i> , 2015 , 63, 1294	13.4	4
103	Postsustained Virological Response Management in Hepatitis C Patients. <i>Seminars in Liver Disease</i> , 2020 , 40, 233-239	7.3	4

102	Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: the plot thickens. <i>Journal of Hepatology</i> , 2012 , 56, 276-8	13.4	4
101	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.. <i>Digestive and Liver Disease</i> , 2022 ,	3.3	4
100	Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. <i>Digestive and Liver Disease</i> , 2021 ,	3.3	4
99	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , 2021 , 41, 2228-2232	7.9	4
98	Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". <i>Journal of Hepatology</i> , 2015 , 63, 1535-6	13.4	3
97	Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma. <i>Updates in Surgery</i> , 2020 , 72, 413-421	2.9	3
96	Screening and surveillance of esophageal varices: Validation of Baveno VI criteria in a cohort of cirrhotic HCV patients. <i>Digestive and Liver Disease</i> , 2016 , 48, e17	3.3	3
95	Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3 year study. <i>Journal of Hepatology</i> , 2018 , 68, S529	13.4	3
94	Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms. <i>Journal of Virological Methods</i> , 2013 , 187, 271-3	2.6	3
93	Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients. <i>BioMed Research International</i> , 2013 , 2013, 580796	3	3
92	Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders. <i>Hepatology</i> , 2013 , 57, 2087	11.2	3
91	1318 FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C IS NOT INFLUENCED BY IL28B POLYMORPHISMS. <i>Journal of Hepatology</i> , 2011 , 54, S519	13.4	3
90	Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011 , 35, 455-64	2.4	3
89	A risk score based on baseline risk factors for predicting mortality in COVID-19 patients. <i>Current Medical Research and Opinion</i> , 2021 , 37, 917-927	2.5	3
88	Return to Work After Coronavirus Disease 2019 Acute Respiratory Distress Syndrome and Intensive Care Admission: Prospective, Case Series at 6 Months From Hospital Discharge. <i>Critical Care Medicine</i> , 2021 , 49, e1157-e1162	1.4	3
87	Virtual Biopsy for Diagnosis of Chemotherapy-Associated Liver Injuries and Steatohepatitis: A Combined Radiomic and Clinical Model in Patients with Colorectal Liver Metastases. <i>Cancers</i> , 2021 , 13,	6.6	3
86	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021 , 53, 612-619	3.3	3
85	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SItN). <i>Journal of Nephrology</i> , 2019 , 31, 685-712	4.8	3

84	Genotype 3 infection in DAA era: Reports of a real life Northern Italy Network for viral hepatitis after 2 years by the start. <i>Digestive and Liver Disease</i> , 2017 , 49, e68	3.3	2
83	Screening of esophagogastric varices: Performance of the Expanded Baveno VI criteria and the platelet 150/MELD 6 strategy in all etiology compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2018 , 68, S734-S735	13.4	2
82	Safety of vedolizumab in liver transplant recipients: A systematic review. <i>United European Gastroenterology Journal</i> , 2019 , 7, 875-880	5.3	2
81	High-resolution melting assay for genotyping of IFNL4-associated dinucleotide variant rs368234815. <i>Clinical Microbiology and Infection</i> , 2014 , 20, O936-8	9.5	2
80	Hepatitis C genotype 3: a tough match for interferon-free regimens. <i>Gastroenterology</i> , 2014 , 146, 1125-1133	13.3	2
79	Is there need for more than one IL28B single nucleotide polymorphism in hepatitis C clinical practice?. <i>Hepatology</i> , 2013 , 57, 416	11.2	2
78	506 UNDETECTABLE HCV-RNA IN TELAPREVIR-TREATED PATIENTS: LOW CONCORDANCE BETWEEN TWO HIGHLY SENSITIVE REAL-TIME PCR ASSAYS. <i>Journal of Hepatology</i> , 2013 , 58, S208	13.4	2
77	Treatment of chronic hepatitis C with pegylated interferon in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura. <i>Transfusion Medicine</i> , 2013 , 23, 66-68	1.3	2
76	934 DIFFERENCES IN HCV GENOTYPE 1 RVR RATES AMONG CLINICAL TRIALS IN EUROPE DEPEND ON HCV RNA ASSAY SENSITIVITY. <i>Journal of Hepatology</i> , 2012 , 56, S364	13.4	2
75	Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients. <i>Journal of Hepatology</i> , 2012 , 56, 1422	13.4	2
74	Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis. <i>Journal of Interferon and Cytokine Research</i> , 2013 , 33, 9-14	3.5	2
73	T-29 Early NK cell activation predicts successful treatment outcome in chronic HCV infection. <i>Digestive and Liver Disease</i> , 2011 , 43, S86	3.3	2
72	A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. <i>Gastroenterology</i> , 2011 , 141, 396-9	13.3	2
71	Genetic variation in interleukin-28B predicts hepatitis C treatment-induced viral clearance in genotype 1 patients: the dawn of a new era?. <i>Gastroenterology</i> , 2010 , 138, 2546-9	13.3	2
70	Telaprevir for hepatitis C re-treatment: an open door on a long and winding road. <i>Gastroenterology</i> , 2010 , 139, 1412-6; discussion 1416	13.3	2
69	291 INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY. <i>Journal of Hepatology</i> , 2010 , 52, S122	13.4	2
68	The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?. <i>Hepatology</i> , 2009 , 49, 702-3; author reply 703-4	11.2	2
67	794 PROSPECTIVE STUDY OF DYSPLASTIC NODULES IN CIRRHOSIS: CORRELATION WITH CT VASCULAR PATTERN, HISTOLOGY AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2009 , 50, S290-S291	13.4	2

66	Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?. <i>Viruses</i> , 2021 , 13,	6.2	2
65	Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 2203-2222	6.2	2
64	New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations		2
63	Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study. <i>Medicine (United States)</i> , 2018 , 97, e11307	1.8	2
62	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Internal and Emergency Medicine</i> , 2018 , 13, 1139-1145	3.7	2
61	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Internal and Emergency Medicine</i> , 2018 , 13, 1139-1145	3.3	2
60	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study. <i>Journal of Hepatology</i> , 2018 , 68, S86	13.4	2
59	Is there an 'ideal' diet for patients with NAFLD?. <i>European Journal of Clinical Investigation</i> , 2021 , e13659	4.6	2
58	Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. <i>Liver International</i> , 2021 ,	7.9	2
57	Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. <i>Antiviral Therapy</i> , 2007 , 12, 1033-40	1.6	2
56	Safety of current antiviral drugs for chronic hepatitis B.. <i>Expert Opinion on Drug Safety</i> , 2022 , 1-7	4.1	2
55	Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. <i>Viruses</i> , 2022 , 14, 1096	6.2	2
54	Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage. <i>Viral Immunology</i> , 2018 , 31, 358-361	1.7	1
53	No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered?. <i>Gastroenterology</i> , 2016 , 150, 1241-1243	13.3	1
52	Managing Patients With Nonalcoholic Fatty Liver Disease: Is It Really Only About Fibrosis?. <i>Gastroenterology</i> , 2018 , 155, 926-928	13.3	1
51	Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 553-4	6.1	1
50	Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study. <i>International Journal of Artificial Organs</i> , 2014 , 37, 803-8	1.9	1
49	Interferon-free oral therapy for hepatitis C: "faraway, so close!". <i>Gastroenterology</i> , 2012 , 142, 1253-4	13.3	1

48	A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations?. <i>Gastroenterology</i> , 2011 , 140, 1347-9	13.3	1
47	Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. <i>Biologics: Targets and Therapy</i> , 2012 , 6, 363-70	4.4	1
46	The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. <i>Journal of Hepatology</i> , 2006 , 44, 825; author reply 825-6	13.4	1
45	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. <i>Blood</i> , 2020 , 136, 6-8	2.2	1
44	Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 341-341	2.2	1
43	Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 839-843	4.1	1
42	The effect of COVID-19 epidemic on vital signs in hospitalized patients: a pre-post heat-map study from a large teaching hospital. <i>Journal of Clinical Monitoring and Computing</i> , 2021 , 1	2	1
41	What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective. <i>United European Gastroenterology Journal</i> , 2021 , 9, 787	5.3	1
40	Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018 , 17, 570-574	2.1	1
39	Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients. <i>Digestive and Liver Disease</i> , 2021 , 53, 1232-1234	3.3	1
38	Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network. <i>European Review for Medical and Pharmacological Sciences</i> , 2016 , 20, 17-19	2.9	1
37	Glecaprevir/Pibrentasvir: The Final Piece in the Hepatitis C Virus Treatment Puzzle?. <i>Gastroenterology</i> , 2018 , 154, 1195-1196	13.3	0
36	Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 9342	2.6	0
35	Critical Care Outreach Team During COVID-19: Ventilatory Support in the Ward and Outcomes. <i>Respiratory Care</i> , 2021 , 66, 928-935	2.1	0
34	High prevalence of multidrug-resistant bacteria in patients with pyogenic liver abscess following liver cancer loco-regional treatments. <i>Liver International</i> , 2021 , 41, 1909-1912	7.9	0
33	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 558-568	3.4	0
32	Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.. <i>Advances in Therapy</i> , 2022 , 1	4.1	0
31	Treatment of chronic hepatitis C: can complexity pave the way towards elimination?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 465-466	18.8	

- 30 Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era?. *Gastroenterology*, **2015**, 149, 500-1 13.3
- 29 Genotype 2 Patients: What is the Optimum Therapy so Far?. *Current Hepatology Reports*, **2015**, 14, 253-259
- 28 12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. *Digestive and Liver Disease*, **2018**, 50, 703-706 3.3
- 27 Reply. *Hepatology*, **2016**, 63, 1052-3 11.2
- 26 Hepatitis C Virus **2014**, 859-877
- 25 Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. *International Journal of Drug Policy*, **2015**, 101669-101669 5.5
- 24 Optimal Management of Hepatitis C Genotype 2 Chronic Infection. *Current Hepatology Reports*, **2014**, 13, 273-278 1
- 23 Reply to: "The Pegylated History continues [Perhaps because both ends (a and b) are true?]" *Journal of Hepatology*, **2012**, 57, 229 13.4
- 22 Insulin resistance and response to telaprevir plus pegylated interferon and ribavirin: a requiem for the HOMA score?. *Gastroenterology*, **2012**, 143, 1685-7 13.3
- 21 Treatment of nonresponder patients with chronic hepatitis C: to repeat or not to repeat? That is the question. *Gastroenterology*, **2009**, 137, 1521-4; discussion 1524 13.3
- 20 Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?. *Journal of Viral Hepatitis*, **2008**, 15, 471 3.4
- 19 The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis. *Gastroenterology*, **2007**, 133, 2076 13.3
- 18 Analisi Economica Associata all'utilizzo Di Due Test (Real-Time PCR-Based) per Valutare La Determinazione Dell'HCV-RNA Nei Pazienti HCV Genotipo 1 in Trattamento Con Duplice o Triplice Terapia. *Global & Regional Health Technology Assessment*, **2017**, 4, grhta.5000248 0.2
- 17 Anemia during Pegylated Interferon-Ribavirin Therapy Results from Both Increase Suppression of Erythroid Differentiation and Hemolysis. *Blood*, **2008**, 112, 4577-4577 2.2
- 16 In Vitro Effect of Ribavirin and Pegylated Interferon on Erythropoiesis. *Blood*, **2008**, 112, 4786-4786 2.2
- 15 Indolent B-Cell Lymphomas Treated Upfront with Antiviral Therapy: a Series of 13 Patients. *Blood*, **2010**, 116, 2876-2876 2.2
- 14 Predictors of Sustained Virological Response After Antiviral Therapy for Chronic Hepatitis C In Patients with Hemophilia: The Role of the Interleukin-28B (IL28B) Polymorphism. *Blood*, **2011**, 118, 2276-2276 2.2
- 13 Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. *Digestive and Liver Disease*, **2021**, 53, 1603-1609 3.3

12	Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 5-6	18.8
11	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Infection</i> , 2019 , 47, 141-168	5.8
10	Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood?. <i>Lancet Haematology</i> , 2021 , 8, e8-e10	14.6
9	No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals. <i>Liver International</i> , 2018 , 38, 2342-2342.	7.9
8	High prevalence of porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels.. <i>Liver International</i> , 2022 ,	7.9
7	Cost Analysis of Platelet Transfusion in Italy for Patients with Chronic Liver Disease and Associated Thrombocytopenia Undergoing Elective Procedures.. <i>ClinicoEconomics and Outcomes Research</i> , 2022 , 14, 205-220	1.7
6	Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges.. <i>World Journal of Gastroenterology</i> , 2022 , 28, 1430-1443	5.6
5	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma 2020 , 15, e0232371	
4	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma 2020 , 15, e0232371	
3	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma 2020 , 15, e0232371	
2	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma 2020 , 15, e0232371	
1	Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: need for a Regional programmatic approach on screening and linkage to care. Commentary. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2021 , 57, 201-204	1.6